Navigation Links
Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Date:2/5/2009

WALTHAM, Mass., Feb. 5 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the third quarter of fiscal year 2009, ended December 31, 2008. Total revenue for the quarter was $6,018,000 compared to $4,664,000 for the third quarter of fiscal year 2008. Total revenue was comprised of Protein A product revenue, and royalty and other revenue. Product revenue for the quarter was $3,294,000 and royalty and other revenue was $2,724,000, comprised primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia(R) (abatacept) and grant revenue from the Muscular Dystrophy Association.

Operating expenses for the third quarter of fiscal year 2009 were $6,556,000 compared to $5,663,000 for the same period in fiscal year 2008. This increase in operating expenses of $893,000 was primarily the result of increased spending associated with advancement of our Phase 3 clinical trial of RG1068 for pancreatic imaging, and initiation of our Phase 2b clinical trial of RG2417 for bipolar depression, as well as increased research and development expenses associated with our program to identify a clinical candidate for Friedreich's ataxia. These increases in spending were partially offset by reductions in legal and other selling, general and administrative expenses.

The net income for the quarter was $18,000 or $0.00 per diluted share, compared to a net loss for the same quarter of fiscal year 2008 of $242,000 or $0.01 per diluted share. Cash, cash equivalents and marketable securities as of December 31, 2008 were $64,509,000 compared to $60,589,000 as of March 31, 2008.

"We are pleased to have advanced our pipeline and achieved strong revenue growth during a quarter marked by continued global financial turmoil," stated Walter C. Herlihy, President and Chief Executive Officer of
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
2. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
3. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
4. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
5. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
6. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
7. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
8. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
9. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
10. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 “We are honored to ... said Ven Thangaraj, CEO of Radiant Sage. “We are ... taking the imaging corelab market to a different level. ... research organizations to efficiently and effectively manage the massive ... to be analyzed and read by trained physicians. Being ...
(Date:8/27/2014)... 2014 Research and Markets has ... Pulp & Paper Industry Report 2014" report to ... Pulp & Paper Industry Report 2014 is a professional ... global enzyme for pulp & paper industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... 2014 Riviera Beach, Florida based ... creation of the Sancilio Scientific Advisory Board (SSAB). ... philosophy of looking to nature for pharmaceutical advancements, ... are based on sound scientific data, analyses, expertise ... provides a vehicle for SCI to receive peer ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Remcom announces ... with new features for the biomedical industry. ... enhanced Biological Thermal Sensor, exclusive to the Bio-Pro version ... version of XFdtd, developed to calculate the biological effects ... has been added to all versions to expand engineers’ ...
Breaking Biology Technology:Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2Global Enzyme for Pulp & Paper Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3
... Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biopharmaceutical ... therapeutics for,the treatment of solid and hematologic cancers, today ... upcoming conferences:, Rodman & Renshaw 10th Annual Healthcare ... Wednesday, November 12, 2008, 2:00 p.m. EST, ...
... MINNEAPOLIS, Nov. 3 ATS Medical, Inc.,(Nasdaq: ... state-of-the-art cardiac,surgery products and services, today announced ... development of the ATS Forcefield(TM),technology. The animal ... regarding the inhibition of platelet adhesion on ...
... Journal published,an article on October 29th describing the ... and featuring quotes from,President and founder Dr. Timothy ... Transfusions: New Efforts to Recycle Blood and Treat ... part of the "The Informed Patient",series written by ...
Cached Biology Technology:Sunesis to Present at Upcoming Conferences 2ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results 2ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results 3Wall Street Journal Highlights Blood Management, Strategic Healthcare Group LLC, and Dr. Timothy Hannon 2
(Date:8/28/2014)... most important crop-producing countries will be fully saturated with ... trends continue, according to a new study led by ... types can already be found in around half the ... advances at its current rate, scientists fear that a ... by pests within the next 30 years. , Crop ...
(Date:8/27/2014)... MADISON, Wis. The mechanical force that a single fungal ... seem vanishingly small, but it plays a heavy role in ... biology. In fact, it may not be too much of ... onto land without the ability to respond to the touch ... Jean-Michel An, a professor of agronomy at the University of ...
(Date:8/27/2014)... -- WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced that it ... units of common stock and warrants at a price ... million, prior to deducting underwriting discounts and commissions and ... warrants are immediately separable and will be issued separately.  ... consists of 2,000 shares of common stock and 2,000 ...
Breaking Biology News(10 mins):New study charts the global invasion of crop pests 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3
... major component in the spice turmeric, when combined with ... and neck cancer cell growth, researchers with UCLA,s Jonsson ... widely used in South Asian and Middle Eastern cooking, ... attributed to its anti-inflammatory effects. Previous studies have shown ...
... and tissues in our bodies grow, develop and interact ... microbial pathogens that invade our bodies and cause infectious ... the methods of culturing and studying human cells have ... impermeable surfaces. While such 2-D culturing and modeling efforts ...
... of Leeds plant scientists has uncovered a snapshot of evolution ... million years ago led flowers to make male and female ... week in the Proceedings of the National Academy of ... a perfect example of how diversity stems from such genetic ...
Cached Biology News:Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 2Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 3The world is not flat: Exploring cells and tissues in three dimensions 2The world is not flat: Exploring cells and tissues in three dimensions 3The world is not flat: Exploring cells and tissues in three dimensions 4100-million-year-old mistake provides snapshot of evolution 2
... Spring offers a large collection of ... fetal tissuea, cell lines, and mouse ... in pHD9 vector. The size of ... be from 200bp to 1000bp by ...
... The IDS Corticosterone kit is a competitive ... corticosterone in mouse or rat serum or ... sole, corticosteroid in rats and mice, and ... birds and reptiles. Most mammals produce both ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Rabbit polyclonal to Nck alpha ( Abpromise for all tested applications). entrezGeneID: 4690 SwissProtID: P16333...
Biology Products: